KR20210127447A - Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients - Google Patents

Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients Download PDF

Info

Publication number
KR20210127447A
KR20210127447A KR1020200045310A KR20200045310A KR20210127447A KR 20210127447 A KR20210127447 A KR 20210127447A KR 1020200045310 A KR1020200045310 A KR 1020200045310A KR 20200045310 A KR20200045310 A KR 20200045310A KR 20210127447 A KR20210127447 A KR 20210127447A
Authority
KR
South Korea
Prior art keywords
uvb
cosmetic composition
piceatannol
skin
skin regeneration
Prior art date
Application number
KR1020200045310A
Other languages
Korean (ko)
Other versions
KR102374039B1 (en
Inventor
박종군
정유헌
정슬아
조하얀
Original Assignee
원광대학교산학협력단
(주)제노코스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원광대학교산학협력단, (주)제노코스 filed Critical 원광대학교산학협력단
Priority to KR1020200045310A priority Critical patent/KR102374039B1/en
Publication of KR20210127447A publication Critical patent/KR20210127447A/en
Application granted granted Critical
Publication of KR102374039B1 publication Critical patent/KR102374039B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/602Glycosides, e.g. rutin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/592Mixtures of compounds complementing their respective functions
    • A61K2800/5922At least two compounds being classified in the same subclass of A61K8/18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a cosmetic composition for skin regeneration containing an Rg2 and piceatannol mixture as an active ingredient. More specifically, the cosmetic composition contains a ginsenoside Rg2 and piceatannol mixture as an active ingredient. Accordingly, the cosmetic composition for skin regeneration containing an Rg2 and piceatannol mixture as an active ingredient according to the present invention has no cytotoxicity, increases the survival rate of skin cells damaged by ultraviolet rays, reduces active oxygen, and also, recovers DNA damaged by ultraviolet rays.

Description

Rg2 및 피세아탄놀 혼합물을 유효성분으로 함유하는 피부 재생용 화장료 조성물 {Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients}Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients}

본 발명은 피부 재생용 화장료 조성물에 관한 것으로, 더욱 상세하게는 진세노사이드 Rg에 피세아탄놀을 함께 혼합함으로써 자외선에 의하여 손상된 피부세포를 재생하고, 손상된 유전자를 회복시킬 수 있는 Rg2 및 피세아탄놀 혼합물을 유효성분으로 함유하는 피부 재생용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for skin regeneration, and more particularly, Rg2 and piseatannol, which can regenerate skin cells damaged by UV rays and restore damaged genes by mixing ginsenoside Rg with piseatannol. It relates to a cosmetic composition for skin regeneration containing the mixture as an active ingredient.

인구 고령화로 안티에이징 시장이 꾸준히 성장하고 있으며, 소득 수준이 높아지면서 미용에 대한 관심이 커지고 있다. 또한 최근 환경오염으로 인한 자외선 증가, 미세먼지 등 피부 노화 및 DNA 상해 요인이 증가하고 있는 추세이다. 이에 따라 피부 보호 및 재생, 주름개선, 미백 등에 효과가 있는 기능성 화장품에 대한 수요 및 시장이 지속적으로 확대되고 있다.The anti-aging market is growing steadily due to an aging population, and interest in beauty is growing as income levels rise. In addition, the factors of skin aging and DNA damage such as increased UV rays and fine dust caused by environmental pollution are increasing recently. Accordingly, the demand and market for functional cosmetics that are effective in skin protection and regeneration, wrinkle improvement, and whitening are continuously expanding.

화장품의 경우 피부에 직접 닿기 때문에 화학성분이 배제된 안전한 화장품에 대한 소비자들의 요구가 늘어나면서 천연 화장품의 시장 규모가 지속적으로 늘어나고 있다. 하지만 한국의 천연물을 활용한 기능성 화장품은 선진국 대비 소재탐색, 소재확보에 있어서 기술격차가 큰 상황으로 기능성 화장품 소재의 다양성이 떨어지며, 단일 기능성만 부각하고 있는 실정이다.In the case of cosmetics, the market size of natural cosmetics is continuously increasing as consumers' demands for safe cosmetics that do not contain chemical ingredients are increasing because they come in direct contact with the skin. However, as for functional cosmetics using natural products in Korea, there is a large technological gap in material search and material securing compared to advanced countries, so the diversity of functional cosmetics materials is low, and only a single function is being emphasized.

전 세계적으로 화장품과 의약품의 경계가 무너지면서 화장품의 안정성과 의약품의 효과성을 겸비한 고기능성 소재 및 복합 기능성 소재에 대한 요구가 증가하고 있는 추세이다.As the boundary between cosmetics and pharmaceuticals is collapsing around the world, the demand for high-functional materials and complex functional materials that combine the stability of cosmetics and the effectiveness of pharmaceuticals is increasing.

한편, 인삼속(Panax sp.)에 존재하는 진세노사이드는 인삼의 약리 효과를 나타내는 주요 활성성분으로 알려져 있다. 이러한 진세노사이드는 이미 많은 연구를 통해 화장료 조성물의 유효성분으로서 개발되어 있는 실정(‘특허문헌 1’ 참고)이나, 섭취하는 것이 아닌 화장품에 사용시 실질적으로 진세노사이드가 피부에 어느정도 수준의 효능을 갖는지는 의견이 분분하다. On the other hand, ginsenosides present in the genus Panax sp. are known as major active ingredients showing the pharmacological effect of ginseng. These ginsenosides have already been developed as active ingredients in cosmetic compositions through many studies (refer to 'Patent Document 1'), but when used in cosmetics rather than ingestion, ginsenosides actually have a certain level of efficacy on the skin. Opinions are divided as to whether

KR 10-2012-0023876 A (2012. 03. 14.)KR 10-2012-0023876 A (2012. 03. 14.)

본 발명은 위와 같은 문제점을 해결하기 위하여 안출된 것으로, 본 발명에서 해결하고자 하는 과제는 진세노사이드 Rg2를 유효성분으로 함유하되, 향료로서 주로 사용되어온 과실의 유효성분을 부가적으로 함유함으로써 기능성을 보완할 수 있는 피부 재생용 화장료 조성물을 제공하는 것이다.The present invention has been devised to solve the above problems, and the problem to be solved in the present invention is to contain ginsenoside Rg2 as an active ingredient, but to increase functionality by additionally containing an active ingredient of fruit that has been mainly used as a flavoring agent. It is to provide a cosmetic composition for skin regeneration that can be supplemented.

위와 같은 과제를 해결하기 위한 본 발명에 따른 Rg2 및 피세아탄놀 혼합물을 유효성분으로 함유하는 피부 재생용 화장료 조성물은 진세노사이드 Rg2(ginsenoside Rg2) 및 피세아탄놀(piceatannol) 혼합물을 유효성분으로 함유하는 것을 기술적 특징으로 한다.A cosmetic composition for skin regeneration containing a mixture of Rg2 and piceatannol as active ingredients according to the present invention for solving the above problems contains a mixture of ginsenoside Rg2 (ginsenoside Rg2) and piceatannol as active ingredients is a technical feature.

또한, 위와 같은 과제를 해결하기 위한 본 발명에 따른 Rg2 및 피세아탄놀 혼합물을 유효성분으로 함유하는 피부 재생용 화장료 조성물의 상기 피부는 자외선에 의해 손상된 피부인 것을 기술적 특징으로 한다.In addition, the skin of the cosmetic composition for skin regeneration containing a mixture of Rg2 and piseatannol as active ingredients according to the present invention for solving the above problems is the skin damaged by ultraviolet rays.

또한, 위와 같은 과제를 해결하기 위한 본 발명에 따른 Rg2 및 피세아탄놀 혼합물을 유효성분으로 함유하는 피부 재생용 화장료 조성물의 상기 진세노사이드 Rg2 및 상기 피세아탄놀은 중량비 기준으로 5:1의 비율로 혼합되는 것을 기술적 특징으로 한다.In addition, in the cosmetic composition for skin regeneration containing a mixture of Rg2 and piseatannol according to the present invention as an active ingredient to solve the above problems, the ginsenoside Rg2 and the piseatannol are in a weight ratio of 5:1 It is a technical feature to be mixed with

본 발명에 따른 Rg2 및 피세아탄놀 혼합물을 유효성분으로 함유하는 피부 재생용 화장료 조성물은 세포독성의 문제가 없고, 자외선에 의하여 손상된 피부세포의 생존율을 증가시키며, 활성산소를 저감시킴으로써 손상된 피부가 재생될 수 있다.The cosmetic composition for skin regeneration containing a mixture of Rg2 and piseatannol according to the present invention as an active ingredient does not have a problem of cytotoxicity, increases the survival rate of skin cells damaged by UV rays, and regenerates damaged skin by reducing active oxygen can be

또한, 자외선에 의하여 손상된 DNA를 회복시킴으로써 피부 재생 뿐만 아니라 손상된 피부 자체의 회복을 유도할 수 있다. In addition, by restoring DNA damaged by UV rays, it is possible to induce not only skin regeneration but also the recovery of damaged skin itself.

도 1은 UVB 처리 전 시료(좌; Rg2, 우; PIC)가 처리된 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프
도 2는 UVB 처리 후 시료(좌; Rg2, 우; PIC)가 처리된 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프
도 3은 UVB 처리 후 복합시료의 농도(좌; PIC가 변수, 우; Rg2가 변수)에 따른 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프
도 4는 UVB 처리 전 복합시료의 농도에 따른 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프
도 5는 UVB 처리 후 복합시료의 농도에 따른 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프
도 6은 UVB 처리 후 DPPH assay 결과를 나타내는 그래프
도 7은 UVB 처리 전후 DCF-DA assay 결과를 나타내는 그래프
도 8은 UVB 처리 전후 복합시료의 농도에 따른 cyclobutene pyrimidine dimer의 발생량을 나타내는 실험결과(위) 및 그래프(아래)
도 9는 DNA 상해회복 관련 단백질 발현 결과를 나타내는 실험결과(위) 및 그래프(아래)
1 is a graph showing the evaluation results of cell viability of HaCaT cells treated with a sample (left; Rg2, right; PIC) before UVB treatment;
2 is a graph showing the evaluation results of cell viability of HaCaT cells treated with samples (left; Rg2, right; PIC) after UVB treatment;
3 is a graph showing the evaluation results of the cell viability of HaCaT cells according to the concentration of the composite sample after UVB treatment (left; PIC variable, right; Rg2 variable)
Figure 4 is a graph showing the evaluation result of the cell viability of HaCaT cells according to the concentration of the composite sample before UVB treatment
5 is a graph showing the evaluation results of the cell viability of HaCaT cells according to the concentration of the composite sample after UVB treatment
6 is a graph showing the results of DPPH assay after UVB treatment
7 is a graph showing the results of DCF-DA assay before and after UVB treatment
8 is an experimental result (top) and graph (bottom) showing the amount of cyclobutene pyrimidine dimer generated according to the concentration of the complex sample before and after UVB treatment
9 is an experimental result (top) and graph (bottom) showing the DNA injury recovery-related protein expression results;

본 명세서 및 청구범위에 사용된 용어나 단어는 "발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙"에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야지, 통상적이거나 사전적인 의미로 한정해서 해석되서는 안 된다.The terms or words used in the present specification and claims conform to the technical spirit of the present invention based on the "principle that the inventor can appropriately define the concept of a term in order to best describe his invention" It should be interpreted as the meaning and concept that

따라서 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 실시예에 불과할 뿐이고, 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형 예들이 있을 수 있음을 이해해야 한다.Therefore, the embodiments described in this specification and the configurations shown in the drawings are only the most preferred embodiments of the present invention, and do not represent all the technical ideas of the present invention, so various equivalents that can replace them at the time of the present application It should be understood that there may be water and variations.

실험준비. 세포배양experimental preparation. cell culture

DNA 상해에 대한 Rg2와 피세아탄놀의 혼합물의 최적 혼합비율 및 이의 효능을 분석하기 위해 인간 각질 세포주인 HaCat 세포를 배양하였다. 이후 UVB 200 J/m2를 조사하고 배지에 Rg2, 피세아탄놀(이하 ‘PIC’라 한다), Rg2와 피세아탄놀의 혼합물(이하‘RP’라 한다)을 다양한 농도로 처리하여 배양한 뒤 실험을 진행하였다.In order to analyze the optimal mixing ratio of a mixture of Rg2 and piceatannol and its efficacy on DNA injury, HaCat cells, a human keratinocyte line, were cultured. After irradiating with UVB 200 J/m 2 , the medium was treated with Rg2, piseatannol (hereinafter referred to as 'PIC'), and a mixture of Rg2 and piseatannol (hereinafter referred to as 'RP') at various concentrations and cultured. The experiment was carried out.

실험예 1. 세포생존율 평가 1(단독시료)Experimental Example 1. Cell viability evaluation 1 (single sample)

세포에 UVB를 조사 전과 후로 나눈 뒤 각각에 대해 시료를 24시간 동안 처리한 뒤 MTT assay를 통해 세포활성도 분석을 측정하였다. After dividing the cells into before and after irradiation with UVB, each sample was treated for 24 hours, and then cell activity analysis was measured by MTT assay.

도 1은 UVB 처리 전 시료(좌; Rg2, 우; PIC)가 처리된 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프 및 도 2는 UVB 처리 후 시료(좌; Rg2, 우; PIC)가 처리된 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프이다.1 is a graph showing the cell viability evaluation results of HaCaT cells treated with samples before UVB treatment (left; Rg2, right; PIC), and FIG. 2 is HaCaT treated with samples after UVB treatment (left; Rg2, right; PIC) It is a graph showing the evaluation result of cell viability of cells.

그 결과, 도 1에 도시된 바와 같이 UVB를 처리하기 전 Rg2의 단독 처리는 100μM까지 세포독성을 나타내지 않았으나, 200μM에서 약간의 세포독성을 나타내었다. PIC의 단독 처리는 20μM까지는 세포독성을 나타내지 않았으나, 40μM에서 약간의 세포독성을 나타내었다. As a result, as shown in Figure 1, Rg2 alone treatment before UVB treatment did not show cytotoxicity up to 100 μM, but showed some cytotoxicity at 200 μM. Treatment with PIC alone did not show cytotoxicity up to 20 μM, but showed some cytotoxicity at 40 μM.

한편, 도 2에 도시된 바와 같이 UVB 조사 후 Rg2의 단독 처리는 농도 의존적으로 새포생존율을 증가시켰으며, 100μM에서 UVB만 조사된 대조군에 비해 세포생존율을 약 20% 증가시켰다. 하지만, 100μM 이상에서는 세포독성이 나타났다. UVB 조사 후 PIC의 단독 처리는 20μM까지 유의한 세포생존율 증가를 나타내지 않았으며 40μM부터 세포독성을 나타낸 것을 알 수 있다. On the other hand, as shown in FIG. 2 , treatment with Rg2 alone after UVB irradiation increased cell viability in a concentration-dependent manner, and increased cell viability by about 20% compared to the control irradiated with UVB alone at 100 μM. However, cytotoxicity was observed above 100 μM. It can be seen that the single treatment of PIC after UVB irradiation did not show a significant increase in cell viability up to 20 μM and showed cytotoxicity from 40 μM.

실험예 2. 세포생존율 평가 2(복합시료)Experimental Example 2. Cell viability evaluation 2 (composite sample)

실험예 1 결과를 바탕으로 Rg2와 PIC가 UVB로 유도되는 상해에 대한 최적의 효능을 가지는 비율을 확립하기 위한 실험을 진행하였다. 세포에 UVB를 조사한 후 UVB에 대해 가장 좋은 세포독성 저감효능을 보인 Rg2 100μM의 농도에 PIC를 다양한 농도로 혼합하여 24시간 동안 처리하였다. Based on the results of Experimental Example 1, an experiment was conducted to establish a ratio of Rg2 and PIC having the optimal efficacy against UVB-induced injury. After irradiating the cells with UVB, PIC was mixed in various concentrations at a concentration of 100 μM of Rg2, which showed the best cytotoxicity reduction effect on UVB, and treated for 24 hours.

또한, UVB에 대해 가장 좋은 세포독성 저감 효능을 보인 PIC 20μM 농도에 Rg2를 다양한 농도로 혼합하여 24시간 동안 처리하였다. In addition, various concentrations of Rg2 were mixed with PIC 20 μM, which showed the best cytotoxicity reduction efficacy against UVB, and treated for 24 hours.

또한, Rg2와 PIC를 5:1로 혼합(RP)한 다음 다양한 농도로 24시간 동안 처리하여 세포생존율을 분석하였다. In addition, the cell viability was analyzed by mixing Rg2 and PIC at a ratio of 5:1 (RP) and then treating them at various concentrations for 24 hours.

도 3은 UVB 처리 후 복합시료의 농도(좌; PIC가 변수, 우; Rg2가 변수)에 따른 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프, 도 4는 UVB 처리 전 복합시료의 농도에 따른 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프 및 도 5는 UVB 처리 후 복합시료의 농도에 따른 HaCaT 세포의 세포생존율 평가 결과를 나타내는 그래프이다.Figure 3 is a graph showing the cell viability evaluation results of HaCaT cells according to the concentration of the composite sample after UVB treatment (left; PIC variable, right; Rg2 variable), Figure 4 is HaCaT cells according to the concentration of the composite sample before UVB treatment 5 is a graph showing the cell viability evaluation result of the HaCaT cells according to the concentration of the composite sample after UVB treatment is a graph showing the cell viability evaluation result.

그 결과, 도 3에 도시된 바와 같이 Rg2 100μM과 PIC 20μM이 혼합되었을 때 UVB만 조사한 대조군에 비해 세포생존율을 약 30% 증가시킨 것을 알 수 있다. As a result, as shown in FIG. 3, it can be seen that when 100 μM of Rg2 and 20 μM of PIC were mixed, the cell viability was increased by about 30% compared to the control irradiated with UVB alone.

이에 따라 Rg2와 PIC가 5:1의 혼합비료 혼합되었을 시 UVB로 인한 세포생존율 감소에 가장 좋은 효과가 있음을 알 수 있다. Accordingly, it can be seen that when Rg2 and PIC are mixed in a ratio of 5:1, it has the best effect on reducing the cell viability due to UVB.

또한, UVB를 조사한 세포에 RP를 처리할 시 농도 의존적으로 세포생존율이 약 30% 증가한 것을 알 수 있다. In addition, it can be seen that the cell viability increased by about 30% in a concentration-dependent manner when UVB-irradiated cells were treated with RP.

실험예 3. 활성산소 저감 분석Experimental Example 3. Active oxygen reduction analysis

자외선에 노출될 경우 세포에는 활성산소가 생산되어 산화적 스트레스가 유도된다. UVB로 유도된 산화적 스트레스에 대한 RP의 효능을 분석하기 위해 DPPH assay를 이용하여 RP의 자유라디칼 소거능을 측정하였고, DCF-DA assay를 이용하여 세포 내 활성산소 저감 효능을 측정하였다. When exposed to ultraviolet light, free radicals are produced in the cells and oxidative stress is induced. In order to analyze the efficacy of RP on UVB-induced oxidative stress, the free radical scavenging ability of RP was measured using the DPPH assay, and the intracellular free radical reduction efficacy was measured using the DCF-DA assay.

도 6은 UVB 처리 후 DPPH assay 결과를 나타내는 그래프 및 도 7은 UVB 처리 전후 DCF-DA assay 결과를 나타내는 그래프이다.6 is a graph showing the DPPH assay results after UVB treatment, and FIG. 7 is a graph showing the DCF-DA assay results before and after UVB treatment.

그 결과, 도 6에 도시된 바와 같이 RP를 3시간 처리 시 자유라디칼 소거능은 농도가 증가할수록 증가하였으며, 표준물질인 아스코빅산(ascorpic acid)과 유사한 자유라디칼 소거능을 나타냈다. As a result, as shown in FIG. 6 , when RP was treated for 3 hours, the free radical scavenging ability increased as the concentration increased, and exhibited a free radical scavenging ability similar to that of ascorbic acid, a standard material.

또한, 도 7에 도시된 바와 같이 UVB에 의해 증가된 활성산소는 RP를 3시간 처리 시에 농도의존적으로 약 40% 감소하였다. In addition, as shown in Figure 7, active oxygen increased by UVB was reduced by about 40% in a concentration-dependent manner when RP was treated for 3 hours.

실험예 4. DNA 상해회복 분석Experimental Example 4. DNA injury recovery analysis

자외선에 노출될 경우 세포에는 상보적이지 않은 피리미딘계 염기기리의 결합으로 Cyclobutene pyrimidine dimer(CPD)와 같은 염기상해가 발생한다. UVB로 유도된 DNA 상해에 대한 RP의 효능은 dot blot으로 측정하였다. When exposed to UV light, cell damage such as cyclobutene pyrimidine dimer (CPD) occurs due to the binding of non-complementary pyrimidine base groups. The efficacy of RP on UVB-induced DNA injury was measured by dot blot.

구체적으로 UVB를 조사한 후 RP를 다양한 농도로 24시간 동안 처리하여 DNA를 추출한 다음, CPD 항체와 반응시켰으며 이를 이미지화하여 CPD의 수준을 UVB만 조사한 대조군 대비 백분율로 산출하였다.Specifically, after irradiating UVB, RP was treated at various concentrations for 24 hours to extract DNA, and then reacted with CPD antibody. By imaging this, the level of CPD was calculated as a percentage compared to the control irradiated only with UVB.

도 8은 UVB 처리 전후 복합시료의 농도에 따른 cyclobutene pyrimidine dimer의 발생량을 나타내는 실험결과(위) 및 그래프(아래)이다.8 is an experimental result (top) and graph (bottom) showing the amount of cyclobutene pyrimidine dimer generated according to the concentration of the composite sample before and after UVB treatment.

그 결과 도 8에 도시된 바와 같이 UVB에 의해 증가된 CPD의 수준은 RP농도 의존적으로 약 60% 감소하였다. As a result, as shown in FIG. 8, the level of CPD increased by UVB was decreased by about 60% in a RP concentration-dependent manner.

실험예 5. DNA 상해회복 관련 단백질 분석Experimental Example 5. DNA injury recovery-related protein analysis

세포에 UVB를 조사한 다음 24시간 동안 RP를 처리한 뒤 DNa 상해회복 관련 단백질인 p-p53과 p21의 수준 변화를 웨스턴 블랏(western blot)을 통해 분석하였다. 구체적으로 UVB를 조사한 후 RP를 다양한 농도로 24시간 동안 처리하여 단백질을 추출한 후 p-p53, p21 항체와 반응시켰으며, 이를 이미지화하여 단백질의 수준을 대조군 대비 백분율로 산출하였다.Cells were irradiated with UVB and then treated with RP for 24 hours, and then the changes in the levels of p-p53 and p21, which are proteins related to DNA injury recovery, were analyzed by western blot. Specifically, after UVB irradiation, RP was treated at various concentrations for 24 hours to extract proteins, and then reacted with p-p53 and p21 antibodies, which were imaged to calculate the protein level as a percentage compared to the control.

도 9는 DNA 상해회복 관련 단백질 발현 결과를 나타내는 실험결과(위) 및 그래프(아래)이다.9 is an experimental result (top) and a graph (bottom) showing the DNA injury recovery-related protein expression results.

그 결과 도 9에 도시된 바와 같이 UVB로 인해 약 2.5배 증가된 p-p53의 발현 수준은 RP 농도 의존적으로 약 25% 감소하였다. UVB로 인해 약 2배 증가된 p21의 발현 수준은 RP 농도 의존적으로 약 35% 감소하였다.As a result, as shown in FIG. 9, the expression level of p-p53 increased by about 2.5 times due to UVB was decreased by about 25% in a RP concentration-dependent manner. The expression level of p21, which was increased by about 2-fold due to UVB, decreased by about 35% in a RP concentration-dependent manner.

Claims (3)

진세노사이드 Rg2(ginsenoside Rg2) 및 피세아탄놀(piceatannol) 혼합물을 유효성분으로 함유하는 것을 특징으로 하는 피부 재생용 화장료 조성물.
A cosmetic composition for skin regeneration, comprising a mixture of ginsenoside Rg2 (ginsenoside Rg2) and piceatannol as an active ingredient.
청구항 1에 있어서,
상기 피부는 자외선에 의해 손상된 피부인 것을 특징으로 하는 피부 재생용 화장료 조성물.
The method according to claim 1,
The skin is a cosmetic composition for skin regeneration, characterized in that the skin damaged by ultraviolet rays.
청구항 1에 있어서,
상기 진세노사이드 Rg2 및 상기 피세아탄놀은 중량비 기준으로 5:1의 비율로 혼합되는 것을 특징으로 하는 피부 재생용 화장료 조성물.
The method according to claim 1,
The cosmetic composition for skin regeneration, characterized in that the ginsenoside Rg2 and the piseatannol are mixed in a ratio of 5:1 based on the weight ratio.
KR1020200045310A 2020-04-14 2020-04-14 Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients KR102374039B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200045310A KR102374039B1 (en) 2020-04-14 2020-04-14 Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200045310A KR102374039B1 (en) 2020-04-14 2020-04-14 Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients

Publications (2)

Publication Number Publication Date
KR20210127447A true KR20210127447A (en) 2021-10-22
KR102374039B1 KR102374039B1 (en) 2022-03-14

Family

ID=78276028

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200045310A KR102374039B1 (en) 2020-04-14 2020-04-14 Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients

Country Status (1)

Country Link
KR (1) KR102374039B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048328A1 (en) 2021-09-27 2023-03-30 코스맥스 주식회사 Oil-dispersed solid cosmetic composition for improving skin elasticity including caffeine and preparation method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120004021A (en) * 2010-07-06 2012-01-12 원광대학교산학협력단 Cosmetic composition comprising extracts of cultured wild ginseng root encapsulated in liposome and preparation method thereof
JP2012046448A (en) * 2010-08-26 2012-03-08 Maruzen Pharmaceut Co Ltd Agent for recovery from ultraviolet damage
KR20120023876A (en) 2010-09-02 2012-03-14 (주)바이오믹스 A cosmetic composition containing ginsenoside re and rh2 complex from red ginseng and the manufacturing method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120004021A (en) * 2010-07-06 2012-01-12 원광대학교산학협력단 Cosmetic composition comprising extracts of cultured wild ginseng root encapsulated in liposome and preparation method thereof
JP2012046448A (en) * 2010-08-26 2012-03-08 Maruzen Pharmaceut Co Ltd Agent for recovery from ultraviolet damage
KR20120023876A (en) 2010-09-02 2012-03-14 (주)바이오믹스 A cosmetic composition containing ginsenoside re and rh2 complex from red ginseng and the manufacturing method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048328A1 (en) 2021-09-27 2023-03-30 코스맥스 주식회사 Oil-dispersed solid cosmetic composition for improving skin elasticity including caffeine and preparation method therefor

Also Published As

Publication number Publication date
KR102374039B1 (en) 2022-03-14

Similar Documents

Publication Publication Date Title
CN111329810B (en) Antioxidant anti-aging cosmetic composition
CN108113914A (en) A kind of essence cream for not adding essence preservative and preparation method thereof
US20180064635A1 (en) Cosmetic composition comprising slime of snail fed with berry fruits and preparation method thereof
CN113117051A (en) Anti-aging transdermal polypeptide preparation and preparation method thereof
KR102374039B1 (en) Cosmetic composition for skin regeneration containing Rg2 and piceatannol mixtures as active ingredients
CN105555366A (en) Extracts fo halimione portulacoides and their application
KR102094061B1 (en) Method of anti-wrinkle and Anti-aging cosmetics compositions using colloidal gold
CN110292543B (en) Biological composition for replacing ultraviolet absorbent and application thereof
EP2092934A1 (en) Ceramide synthesis accelerators, cosmetic preparation, skin preparation for external use, method of preventing aging, and method of diminishing wrinkle
JP2001122758A (en) COSMETIC FOR PROTECTING AND IMPROVING AGED SKIN HAVING AGEs DEGRADING ACTIVITY
CN108434053A (en) A kind of Essence and preparation method thereof to lubricate the skin and muscle that has effects that compact
KR100658296B1 (en) A cosmetic composition containing organic germanium for wrinkle reduction
CN115177565B (en) Whitening and skin brightening composition and application thereof in cosmetics
CN113171319B (en) Instant and long-acting anti-aging wrinkle-removing compound plant extract and preparation method and application thereof
CN115414293A (en) Anti-aging composition and application thereof
EP2747739B1 (en) Dermocosmetic compositions based on a synergistic combination of colloidal silver and deoxyribonucleic acid
JP2004149424A (en) Cosmetic and method for improving humectant function of cosmetic
KR100205499B1 (en) Basic cosmetic compositions having wrinkle-suppressing effect without skin-irritation
CN108652991B (en) A kind of preparation method of the composition with smooth skin effect
KR101252468B1 (en) Cosmetics composition for skin troubles
FR3049461A1 (en) USE OF A PLANT EXTRACT OF POUTERIA LUCUMA FRUIT IN A COSMETIC COMPOSITION
EP2937075A1 (en) Skin barrier protective ingredient and cosmetic and/or dermatological formulation containing the same
JP2006282536A (en) Super oxide-eliminating agent, free radical-eliminating agent, hydrogen peroxide-eliminating agent and external preparation for skin
TW202038903A (en) Use of compound essential oil composition for regulating the gene expression level of mmp, mc1r, krt, tert, terc, and/or ogg1
JP2005029494A (en) Melanocyte proliferation inhibitor and cosmetic containing the same

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant